Printer Friendly

Biochem Pharma succeeds in invalidating Emory University's Australian patent application relating to 3TC.

BioChem Pharma, Inc. (Laval, Canada; 450-978-7938) announced that the Opposition Division of the Australian Patent Office rejected Emory University's (Atlanta, GA) patent application (Australian Patent Application 658136) relating to 3TC. 3TC (lamivudine) is the company's flagship discovery and the world's most prescribed treatment for HIV infection and AIDS, and has also recently been launched in some countries and is rapidly gaining regulatory approvals worldwide as the first oral once-daily antiviral for the treatment of chronic hepatitis B infection.

This decision is in line with the European Patent Office Opposition Division's recent decisions dismissing Emory oppositions against BioChem Pharma's pioneering patents covering compositions of matter for a wide range of nucleoside analogues (European Patent 337 713) and 3TC (European Patent 382 526).

Francesco Bellini, chief executive officer, BioChem Pharma, said, ``We are very pleased that the Australian Patent Office has agreed with BioChem's position that the Emory Australian patent application is invalid. This latest decision by the Australian Patent Office joins the European Patent Office decisions upholding what we have consistently maintained - we are the sole and true inventors of 3TC."

BioChem Pharma is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention, detection and treatment of human diseases with a focus in the anticancer and anti-infective areas.

3TC is a trademark of the Glaxo Wellcome (London, United Kingdom) group of companies.
COPYRIGHT 1999 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Comment:Biochem Pharma succeeds in invalidating Emory University's Australian patent application relating to 3TC.
Publication:BIOTECH Patent News
Geographic Code:1CANA
Date:Aug 1, 1999
Words:229
Previous Article:Cortex to receive additional claims for enhancement of neurotrophic factor expression.
Next Article:Kinetek Pharmaceuticals awarded patent for KP-102, orally active type 2 diabetes therapy.
Topics:


Related Articles
BioChem Pharma says Emory patent is invalid and will not affect sales of 3TC.
United States Judge grants Biochem's motion to say 3TC patent case
Idun Pharmaceuticals signs exclusive licensing agreement with Emory University for cell-free apoptosis patent
Shire obtains positive outcome in Biochem patent litigation.
Enzo Biochem files suit against eight Life Science companies. (Executive Briefing).
Transkaryotic encouraged by Federal Circuit decision.
ROYALTY PHARMA/INNEXUS SIGN PACT FOR DXL ANTIBODY.
Court dismisses claims in Enzo Biotech v. Applied Biosystems.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters